Isatuximab with VRd can benefit newly diagnosed multiple myeloma transplant ineligible patients
Prof Franco Locatelli talks to ecancer at the ALL Assembly 2018 Meeting in Amsterdam about the novel therapies for paediatric B-ALL.
Prof Locatelli explains that immunotherapy in particular has several outstanding approaches that can really impact the natural course of the disease.
He adds we should not overlook the great results obtained using chemotherapy but there is still a great need to develop new therapies due to reaching a ceiling with chemotherapy intensity.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.
Isatuximab with VRd can benefit newly diagnosed multiple myeloma transplant ineligible patients
Understanding the remaining unmet needs in a post ASCT NDMM setting
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Comment: Trial updates from GALAXIES Lung-201 and RELATIVITY-104 in NSCLC
ESMO 2024: Latest in EGFR mutated NSCLC
ASCO 2024: Lung cancer highlights
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
Multiple myeloma in a resource constrained setting
Relapsed refractory multiple myeloma